Prognostic Impact of Squamous Cell Carcinoma Antigen During Neoadjuvant Chemotherapy for Patients With Esophageal Squamous Cell Carcinoma Treated With Minimally Invasive Esophagectomy
Anticancer Research · 2024
DOI: 10.21873/anticanres.17374 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2024. Verfasst von Rikuya Torigoe und 12 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastrointestinal Surgery, Department of Surgery, Graduate School of Medicine, Kobe University, Kobe, Japan. Hauptthemen laut MEDLINE: Esophagectomy, Serpins, Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND/AIM: Squamous cell carcinoma antigen (SCC) is widely used as a tumor marker for esophageal cancer. In this study, we investigated the relationship between SCC and long-term outcomes in patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy (NAC) followed by minimally invasive esophagectomy (MIE). PATIENTS AND METHODS: Between 2010 and 2018, 124 patients with ESCC who underwent MIE after NAC (cisplatin plus 5-fluorouracil) were included. Patients were divided into low and high groups based on their pre-NAC SCC level, according to the cut-off value determined using a receiver operating characteristic curve. These two patient groups were further divided into subgroups by receiver operating characteristics according to whether SCC was low or high after NAC. RESULTS: For overall survival (OS), the cut-off value for SCC pre-NAC was 0.9 ng/ml. Ninety-six patients were in the high SCC group (≥0.9 ng/ml) and 28 patients were in the low SCC group (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastrointestinal Surgery, Department of Surgery, Graduate School of Medicine, Kobe University, Kobe, Japan.
- Division of Gastrointestinal Surgery and Surgical Oncology, Graduate School of Medicine, Toon, Japan oshikiri.taro.th@ehime-u.ac.jp.
Zitieren
APA
Torigoe, R., Oshikiri, T., Goto, H., Koterazawa, Y., Sawada, R., Ikeda, T., Harada, H., Urakawa, N., Hasegawa, H., Kanaji, S., Yamashita, K., Matsuda, T., & Kakeji, Y. (2024). Prognostic Impact of Squamous Cell Carcinoma Antigen During Neoadjuvant Chemotherapy for Patients With Esophageal Squamous Cell Carcinoma Treated With Minimally Invasive Esophagectomy. Anticancer Research. https://doi.org/10.21873/anticanres.17374
Vancouver
Torigoe R, Oshikiri T, Goto H, Koterazawa Y, Sawada R, Ikeda T, et al. Prognostic Impact of Squamous Cell Carcinoma Antigen During Neoadjuvant Chemotherapy for Patients With Esophageal Squamous Cell Carcinoma Treated With Minimally Invasive Esophagectomy. Anticancer Research. 2024. doi:10.21873/anticanres.17374
BibTeX
@article{Torigoe2024,
author = {Torigoe, Rikuya and Oshikiri, Taro and Goto, Hironobu and Koterazawa, Yasuhumi and Sawada, Ryuichiro and Ikeda, Taro and Harada, Hitoshi and Urakawa, Naoki and Hasegawa, Hiroshi and Kanaji, Shingo and Yamashita, Kimihiro and Matsuda, Takeru and Kakeji, Yoshihiro},
title = {Prognostic Impact of Squamous Cell Carcinoma Antigen During Neoadjuvant Chemotherapy for Patients With Esophageal Squamous Cell Carcinoma Treated With Minimally Invasive Esophagectomy},
journal = {Anticancer Research},
year = {2024},
doi = {10.21873/anticanres.17374}
}
EUVIMED